N-methyl-D-aspartate and sigma-ligands change the production of interleukins 8 and 10 in lymphocytes through modulation of the NMDA glutamate receptor.
Human T lymphocytes express both ionotropic and metabotropic glutamate receptors that control immune responses, cell activation, maturation and death. In this study, we examined the effect of N-methyl-D-aspartate (NMDA) and sigma1-receptor ligands on the secretion of the proinflammatory chemokine interleukin 8 (IL-8) and the anti-inflammatory cytokine interleukin 10 (IL-10) in human leukemia Jurkat cells and peripheral blood lymphocytes (PBLs). We have shown that NMDA increased IL-8 and decreased IL-10 secretion and that sigma-ligands modulated the action of NMDA. Moreover, the effects of NMDA and sigma-ligands were interrelated with the nitric oxide (NO) content, suggesting that the intracellular concentration of NO could play a major role in the synthesis of cytokines. Western blots against the NR2A and NR2B subunits of the NMDA glutamate receptor revealed that long-term (48 h) treatment of PBLs with glutamate at concentrations within normal plasma levels (1 x 10(-5)M), in contrast to low concentrations (0.3 x 10(-6)M), downregulates the NR2A subunit, probably by internalization. Furthermore, we found that PBLs with noninternalized NR2A secreted less IL-10 than lymphocytes with downregulated NR2A; under these conditions, the transcriptional activity of NF-kappaB was increased whereas the transcriptional activity of c-Fos was decreased. These findings implicate that the activities of NF-kappaB and c-Fos control the expression of the IL8 and IL10 genes, depending on the subunit composition of the NMDA receptor. In conclusion, we suggest that lymphocytes express an active NMDA receptor only in a low-glutamate milieu.
Kvaratskhelia
Eka
E
Institute of Medical Biotechnology, Tbilissi, Georgia.
Maisuradze
Ekaterine
E
Dabrundashvili
Nino G
NG
Natsvlishvili
Nino
N
Zhuravliova
Elene
E
Mikeladze
David G
DG
D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D018698:Glutamic Acid / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D016209:Interleukin-8 / Q000235:genetics*; D007378:Interleukins / Q000276:immunology / Q000378:metabolism*; D019169:Jurkat Cells; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D015213:Neuroimmunomodulation / Q000187:drug effects / Q000502:physiology*; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000378:metabolism*; D017480:Receptors, sigma / Q000819:agonists* / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D018690:Excitatory Amino Acid Agonists; D016209:Interleukin-8; D007378:Interleukins; D016328:NF-kappa B; C120997:NR2A NMDA receptor; C121001:NR2B NMDA receptor; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D016194:Receptors, N-Methyl-D-Aspartate; D017480:Receptors, sigma; D016753:Interleukin-10; D018698:Glutamic Acid